<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211017052785N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-26</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the effectiveness of Rosa canina L. fruit syrup on hypertension, cholesterol and anxiety In patients with hypertension</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effectiveness of Rosa canina L. fruit syrup on hypertension, cholesterol and anxiety In patients with hypertension A double-blind randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62432</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants are divided into two groups by stratified block randomization, one group receives medication and the other receives placebo.Patients (after completing the lifestyle questionnaire and excluding people who receive the upper or lower third of the score) are divided into six groups based on the score of the lifestyle questionnaire, and each of them by designing 4 blocks and selecting blocks through the lottery, they receive one of two drug or placebo options, respectively, based on the block plan, Blinding description: The drugs used in the present study were prepared by the second executor, which has nothing to do with sampling and prescribing drugs. It is prepared in anonymous packs and given to the researcher. The contents of the packs remain completely confidential and will only be available to the drug manufacturer. The name of the medicine will be given to the personnel when the side effects of the medicine occur. The placebo is prepared by considering the necessary standards in color, smell, taste, shape, etc.</study_design>
      <phase>2</phase>
      <hc_freetext>HTN.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: To prepare Rosa syrup (according to USP 39 – NF 34, Second Supplement Commentary, June 1, 2016): 100 grams of washed Nastaran fruit soaked in 1000 cc of water, after 3 hours, boiled for 10 minutes and cooled in the laboratory. After cooling, we filter the contents of the container with a filter and concentrate the obtained product using a benmary. From 100 grams of Nastaran fruit, 8 grams of dry extract obtained from the extract obtained, 5 grams of it are brought to 100 grams using USP syrup making model with 7.66 grams of honey and 28.5 grams of water. The resulting syrup is poured into 120 cc sterile jars and sealed and sterilized by autoclave. The designed label is then installed and delivered for clinical trial. The raw materials of the medicine are prepared from reliable sources and the initial evaluation of its quality is done. Intervention 2: Control group: Placebo is prepared by considering the necessary standards in color, smell, taste, shape, etc. It will be consumed at a rate of 10cc once a day, half an hour before lunch and for a period of eight weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as information about the main consequences, can be shared by inserting it in the study article.

When:
Access period starts 8 months after the results are published

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
Using data to advance scientific goals

Where to obtain:
Dr. Maarefvand
dr.m.maarefvand@gmail.com

How to obtain:
Send the request for information via the announced gmail and the party will receive a response within a maximum of two weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mina Maarefvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>45 meters from Golshahr - Saffarian Alley - Deputy of Research and Technology</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198764653</zip>
        <telephone>+98 26 3464 3774</telephone>
        <email>dr.m.maarefvand@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mina Maarefvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>45 meters from Golshahr - Saffarian Alley - Deputy of Research and Technology</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3198764653</zip>
        <telephone>+98 26 3464 3705</telephone>
        <email>dr.m.maarefvand@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Men and women in the age of 35 to 65 years with high blood pressure
Systolic blood pressure greater than or equal to 130 to 159 and diastolic blood pressure greater than or equal to 85 to 99 mm Hg</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant and lactating women
Patients with high normal blood pressure and grade 1 who have cardiovascular disease, especially coronary artery disease or grade 4 kidney failure or diabetes that leads to organ damage or grade 1 with chronic kidney failure grade 3 or diabetes without organ damage or organ damage due to high blood pressure The above is already specified in them.
G6PD, hemochromatosis
Taking medications such as warfarin, aspirin and lithium</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I10</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Essential (primary) hypertension</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: To prepare Rosa syrup (according to USP 39 – NF 34, Second Supplement Commentary, June 1, 2016): 100 grams of washed Nastaran fruit soaked in 1000 cc of water, after 3 hours, boiled for 10 minutes and cooled in the laboratory. After cooling, we filter the contents of the container with a filter and concentrate the obtained product using a benmary. From 100 grams of Nastaran fruit, 8 grams of dry extract obtained from the extract obtained, 5 grams of it are brought to 100 grams using USP syrup making model with 7.66 grams of honey and 28.5 grams of water. The resulting syrup is poured into 120 cc sterile jars and sealed and sterilized by autoclave. The designed label is then installed and delivered for clinical trial. The raw materials of the medicine are prepared from reliable sources and the initial evaluation of its quality is done.</i_keyword>
      <i_keyword>Control group: Placebo is prepared by considering the necessary standards in color, smell, taste, shape, etc. It will be consumed at a rate of 10cc once a day, half an hour before lunch and for a period of eight weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic and diastolic blood pressure. Timepoint: First visit and then every two weeks until the eighth week. Method of measurement: Digital sphygmomanometer.</prim_outcome>
      <prim_outcome>Blood HDL and LDL levels. Timepoint: Beginning and end of the trial. Method of measurement: Laboratory experiment.</prim_outcome>
      <prim_outcome>Severity of anxiety. Timepoint: Beginning and end of the trial. Method of measurement: Hamilton anxiety questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-26</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>45 meters from Golshahr - Saffarian Alley - Deputy of Research and Technology Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
